Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 376

1.

Impact of preprocedural TIMI flow on myocardial perfusion, distal embolization and mortality in patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb/IIIa inhibitors.

Maioli M, Zeymer U, van 't Hof AW, Gibson CM, Dudek D, Bellandi F, Noc M, Secco GG, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Huber K, De Luca G; EGYPT Cooperation.

J Invasive Cardiol. 2012 Jul;24(7):324-7.

2.

Impact of distal embolization on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

De Luca G, Gibson CM, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Arntz HR, Dudek D, Rakowski T, Gyongyosi M, Huber K, van't Hof AW.

J Thromb Thrombolysis. 2010 Jul;30(1):23-8. doi: 10.1007/s11239-009-0419-y.

PMID:
19921103
3.

Impact of advanced age on myocardial perfusion, distal embolization, and mortality patients with ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors.

De Luca G, van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Secco GG, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D.

Heart Vessels. 2014 Jan;29(1):15-20. doi: 10.1007/s00380-013-0323-4. Epub 2013 Mar 14.

PMID:
23494604
4.

Impact of time-to-treatment on myocardial perfusion after primary percutaneous coronary intervention with Gp IIb-IIIa inhibitors.

De Luca G, Gibson MC, Hof AW, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel MH, Secco GG, Emre A, Dudek D, Rakowski T, Gyongyosi M, Huber K, Bellandi F; EGYPT cooperation.

J Cardiovasc Med (Hagerstown). 2013 Nov;14(11):815-20. doi: 10.2459/JCM.0b013e32835fcb38.

PMID:
23519096
5.

Time-related impact of distal embolisation on myocardial perfusion and survival among patients undergoing primary angioplasty with glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

De Luca G, Gibson CM, Huber K, Dudek D, Cutlip D, Zeymer U, Gyöngyösi M, Bellandi F, Noc M, Arntz HR, Maioli M, Secco GG, Zorman S, Gabriel HM, Emre A, Rakowski T, Van't Hof AW; EGYPT cooperation.

EuroIntervention. 2012 Aug;8(4):470-6. doi: 10.4244/EIJV8I4A74.

6.

Association between advanced Killip class at presentation and impaired myocardial perfusion among patients with ST-segment elevation myocardial infarction treated with primary angioplasty and adjunctive glycoprotein IIb-IIIa inhibitors.

De Luca G, Gibson CM, Huber K, Zeymer U, Dudek D, Cutlip D, Bellandi F, Noc M, Emre A, Zorman S, Gabriel HM, Maioli M, Rakowski T, Gyöngyösi M, Van't Hof AW; EGYPT Cooperation.

Am Heart J. 2009 Sep;158(3):416-21. doi: 10.1016/j.ahj.2009.06.029.

PMID:
19699865
7.

Diabetes mellitus is associated with distal embolization, impaired myocardial perfusion, and higher mortality in patients with ST-segment elevation myocardial infarction treated with primary angioplasty and glycoprotein IIb-IIIa inhibitors.

De Luca G, Gibson CM, Bellandi F, Noc M, Dudek D, Zeymer U, Arntz HR, Cutlip D, Maioli M, Zorman S, Mesquita Gabriel H, Emre A, Rakowski T, Gyongyosi M, Huber K, Van't Hof AW.

Atherosclerosis. 2009 Nov;207(1):181-5. doi: 10.1016/j.atherosclerosis.2009.03.042. Epub 2009 Apr 5.

PMID:
19426981
8.

Gender-related differences in outcome after ST-segment elevation myocardial infarction treated by primary angioplasty and glycoprotein IIb-IIIa inhibitors: insights from the EGYPT cooperation.

De Luca G, Gibson CM, Gyöngyösi M, Zeymer U, Dudek D, Arntz HR, Bellandi F, Maioli M, Noc M, Zorman S, Gabriel HM, Emre A, Cutlip D, Rakowski T, Huber K, van't Hof AW.

J Thromb Thrombolysis. 2010 Oct;30(3):342-6. doi: 10.1007/s11239-010-0451-y.

PMID:
20213259
9.

Impact of time from symptom onset to drug administration on outcome in patients undergoing glycoprotein IIb-IIIa facilitated primary angioplasty (from the EGYPT cooperation).

De Luca G, Van't Hof AW, Gibson CM, Cutlip D, Zeymer U, Noc M, Maioli M, Zorman S, Gabriel HM, Emre A, Rakowski T, Gyongyosi M, Huber K, Bellandi F, Dudek D; EGYPT cooperation.

Am J Cardiol. 2015 Mar 15;115(6):711-5. doi: 10.1016/j.amjcard.2014.12.030. Epub 2015 Jan 6.

PMID:
25655867
10.
11.

Impact of multivessel disease on myocardial perfusion and survival among patients undergoing primary percutaneous coronary intervention with glycoprotein IIb/IIIa inhibitors.

De Luca G, Gibson M, Cutlip D, Huber K, Dudek D, Bellandi F, Noc M, Maioli M, Zorman S, Zeymer U, Secco GG, Mesquita Gabriel H, Emre A, Arntz HR, Rakowski T, Gyongyosi M, Hof AW; EGYPT Cooperation.

Arch Cardiovasc Dis. 2013 Mar;106(3):155-61. doi: 10.1016/j.acvd.2012.12.007. Epub 2013 Apr 2.

12.

Early glycoprotein IIb-IIIa inhibitors in primary angioplasty (EGYPT) cooperation: an individual patient data meta-analysis.

De Luca G, Gibson CM, Bellandi F, Murphy S, Maioli M, Noc M, Zeymer U, Dudek D, Arntz HR, Zorman S, Gabriel HM, Emre A, Cutlip D, Biondi-Zoccai G, Rakowski T, Gyongyosi M, Marino P, Huber K, van't Hof AW.

Heart. 2008 Dec;94(12):1548-58. doi: 10.1136/hrt.2008.141648. Epub 2008 May 12. Review.

13.

Effect of tirofiban therapy on ST segment resolution and clinical outcomes in patients with ST segment elevated acute myocardial infarction undergoing primary angioplasty.

Uyarel H, Uzunlar B, Unal Dayi S, Tartan Z, Samur H, Kasikcioglu H, Akgul O, Simsek D, Erdem I, Okmen E, Cam N.

Cardiology. 2006;105(3):168-75. Epub 2006 Feb 13.

PMID:
16479104
14.

The impact of GP IIb/IIIa inhibitors during primary percutaneous coronary intervention in acute myocardial infarction patients.

Lavi S, Gruberg L, Kapeliovich M, Hammerman H, Boulos M, Grenadier E, Aronson D, Markiewicz W, Beyar R.

J Invasive Cardiol. 2005 Jun;17(6):296-9.

PMID:
16003002
15.

Administration of eptifibatide during transfer for primary PCI in patients with STEMI: effect on Pre-PCI TIMI flow and its correlation with pain-to-therapy time.

Aquilina M, Varani E, Balducelli M, Vecchi G, Frassineti V, Maresta A.

J Invasive Cardiol. 2009 Mar;21(3):115-20.

PMID:
19258642
16.

A comparison of abciximab and small-molecule glycoprotein IIb/IIIa inhibitors in patients undergoing primary percutaneous coronary intervention: a meta-analysis of contemporary randomized controlled trials.

Gurm HS, Tamhane U, Meier P, Grossman PM, Chetcuti S, Bates ER.

Circ Cardiovasc Interv. 2009 Jun;2(3):230-6. doi: 10.1161/CIRCINTERVENTIONS.108.847996. Epub 2009 Apr 21.

17.

Facilitated angioplasty with combo therapy among patients with ST-segment elevation myocardial infarction: a meta-analysis of randomized trials.

De Luca G, Marino P.

Am J Emerg Med. 2009 Jul;27(6):683-90. doi: 10.1016/j.ajem.2008.05.021.

PMID:
19751625
18.

Timing of glycoprotein IIb/IIIa inhibitor use and outcomes among patients with non-ST-segment elevation myocardial infarction undergoing percutaneous coronary intervention (results from CRUSADE).

Tricoci P, Peterson ED, Chen AY, Newby LK, Harrington RA, Greenbaum AB, Cannon CP, Gibson CM, Hoekstra JW, Pollack CV Jr, Ohman EM, Gibler WB, Roe MT.

Am J Cardiol. 2007 May 15;99(10):1389-93. Epub 2007 Mar 26.

PMID:
17493466
19.

[Glycoprotein IIb/IIIa platelet blockers in acute myocardial infarct treated with primary coronary angioplasty].

Kala P, Poloczek M, Bocek O, Jerábek P, Neugebauer P, Kosová J, Semrád B.

Vnitr Lek. 2002 Aug;48(8):736-41. Czech.

PMID:
12425204
20.

Impact of hypertension on distal embolization, myocardial perfusion, and mortality in patients with ST segment elevation myocardial infarction undergoing primary angioplasty.

De Luca G, van't Hof AW, Huber K, Gibson CM, Bellandi F, Arntz HR, Maioli M, Noc M, Zorman S, Zeymer U, Gabriel HM, Emre A, Cutlip D, Rakowski T, Gyongyosi M, Dudek D; EGYPT cooperation.

Am J Cardiol. 2013 Oct 15;112(8):1083-6. doi: 10.1016/j.amjcard.2013.05.053. Epub 2013 Aug 1.

PMID:
23910428
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk